On August 2, with the approval of the Food and Drug Department (FDD) of the Lao Ministry of Health, acalabrutinib, produced by TLPH, was officially approved for marketing. The approved Acaluni (acalabrutinib), trade name Acaluni, capsules, the specification is 100mg/capsule, 60 capsules/bottle.

Acalabrutinib is an oral BTK inhibitor. In October 2017, acalabrutinib was approved by the FDA after being granted breakthrough therapy and accelerated approval successively. Marketed for patients with mantle cell lymphoma who have previously received other therapies; in 2019, acalabrutinib was approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia based on phase III clinical studies ELEVATE-TN and ASCEND studies Adult patients with lymphoma (SLL).

So far, TLPH has two generations of BTK inhibitors such as ibrutinib and acalabrutinib. With the same quality, it provides more treatment options for patients with hematological tumors.

It is reported that the broad-spectrum anticancer drug Larotrectinib, trade name Larotreni, was also approved on the same day. As an iconic generic drug manufacturing company in Laos, TLPH stated that it will continue to increase investment in the research and development and production of high-quality drugs by taking the launch of new drugs as an opportunity, and continue to provide patients in countries along the "Belt and Road" with "safe, efficient, affordable” drug solutions.